July 25, 2007 – Accuray Inc. featured its Xsight Lung Tracking System designed for the non-invasive treatment of lung tumors, at the American Association of Physicists in Medicine (AAPM) annual meeting in Minneapolis, MN.
Working seamlessly with Accuray’s CyberKnife System and Synchfony Respiratory Tracking System, the Xsight Lung Tracking system uses the body’s soft tissue to directly track targets with radiosurgical accuracy. The system delivers highly specialized soft tissue tracking by using the actual image intensity of the lung tumor to target the beam, therefore eliminating the need in some cases for implanted fiducial markers.
An additional tool in the treatment of lunch cancer is Accuray’s Monte Carlo dose calculation methodology, which is currently pending FDA 510(k) clearance. Accuray’s Monte Carlo dose calculation is designed to be fast and accurate, reportedly enabling clinicians to more precisely determine, in a matter of minutes, the intensity of radiation to be delivered in areas where tissue densities vary.
For more information: www.accuray.com
July 17, 2026 
